IMFINZI mechanism of action

The PD-L1 pathway plays a key role in tumour progression1-5

Expression of PD-L1 is an adaptive immune response that helps tumours evade detection and elimination by the immune system6

  • By binding to its receptors, PD-L1 reduces cytotoxic T cell activity, proliferation, and cytokine production6
  • Increased PD-L1 expression following radiation has been observed in pre-clinical models1-5

Radiation primes the immune system; IMFINZI enables the immune response1-5,7

CD80: cluster of differentiation 80; PD-1: programmed cell death-1

PREVIOUS
There is an unmet need for patients with Stage III NSCLC8,9
LEARN MORE ABOUT NSCLC

NEXT
IMFINZI is the first and only immunotherapy to improve OS and PFS in a Phase III trial6
SEE THE RESULTS

References: 1. Dovedi SJ, Adlard AL, Lipowska-Bhalla G, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. 2014;74(19):5458-5468. 2. Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124(2):687-695. 3. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol. 2005;174(12):7516-7523. 4. Reits EA, Hodge JW, Herberts CA, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 2006;203(5):1259-1271. 5. Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, Hodge JW. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res. 2004;64(12):4328-4337. 6. IMFINZI EU SmPC, June 2020. 7. Stewart R, Morrow M, Hammond SA, et al. Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody. Cancer Immunol Res. 2015;3(9):1052-1062. 8. Postmus PE, Kerr KM, Oudkerk M, et al; ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl 4):iv1-iv21. 9. Hanna N. Current standards and clinical trials in systemic therapy for stage III lung cancer: what is new? Am Soc Clin Oncol Educ Book. 2015:e442-e447.